STANDARD BIOTOOLS INC Stock Price, News & Analysis

Illumina (NASDAQ: ILMN) announced on Nov 10, 2025 that Illumina Protein Prep, commercially launched in September, is in use by more than 40 customers across 16 sites and has processed over 40,000 samples, offering a discovery panel of > 9,500 proteins at a claimed low cost per protein target.

Customers include Sydney Mass Spectrometry (first Asia Pacific site), Genomics England (reported a 7.5% increase in disease classification when integrating proteomics with genomics), and PRECISE-SG100K (running 10,000 plasma samples). Illumina also noted a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, subject to regulatory clearance.

Standard BioTools (NASDAQ: LAB) reported third quarter 2025 results for the quarter ended September 30, 2025, showing $19.6M revenue from continuing operations and $217.0M cash and equivalents on hand. Combined company revenue for Q3 was $46.2M. The company implemented an operational restructuring in September expected to deliver over $40M in annualized cost savings, and reiterated a target to reach positive adjusted EBITDA in 2026. Q3 continuing operations revenue declined 11% year-over-year with consumables down 17% and instruments down 3%. Gross margin from continuing operations was ~48.5% (non-GAAP 53.5%). Net loss from continuing operations was $31.7M and adjusted EBITDA loss was $16.5M. The company expects ~$550M in cash and equivalents at closing of the Illumina transaction in H1 2026 and maintained FY2025 combined revenue guidance of $165M–$175M.

Standard BioTools (NASDAQ: LAB) announced it will publish third quarter 2025 financial results on Tuesday, November 4, 2025.

The company said the results will be released after U.S. market close.

Illumina (NASDAQ:ILMN) has launched Illumina Protein Prep, a groundbreaking NGS-based proteomics assay capable of measuring 9,500 unique human protein targets. This launch follows the company's agreement to acquire SomaLogic, strengthening its position in the proteomics market.

The technology has demonstrated significant impact through early access programs, with 30,000 samples processed using the 6K assay and over 6,000 samples with the 9.5K assay. Notable success includes Genomics England's implementation in their 100,000 Genomes Project, which achieved a 7.5% increase in diagnostic yield for rare diseases.

The solution combines Illumina NovaSeq sequencing platforms with DRAGEN Protein Quantification and Connected Multiomics software, enabling researchers to streamline analysis from discovery to therapeutic development. The company has also announced a pilot program with UK Biobank to analyze 50,000 samples using this technology.

Standard BioTools (NASDAQ:LAB) reported Q2 2025 financial results, highlighting a strategic transformation with the sale of SomaLogic to Illumina for up to $425 million in cash plus future royalties. Q2 revenue from continuing operations was $21.8 million, down 3% year-over-year. The company reported $240 million in cash and expects at least $550 million post-Illumina transaction closure.

Key metrics include consumables revenue of $10.5 million (up 18% YoY), instruments revenue of $5.2 million (down 26% YoY), and services revenue of $6.1 million (down 8% YoY). The company improved its net loss to $17.7 million from $25.4 million in Q2 2024. For FY2025, Standard BioTools expects combined revenue of $165-175 million, with continuing operations revenue of $78-83 million.

Standard BioTools (NASDAQ:LAB) announced that PRECISE-SG100K has selected their SomaScan 11K Assay to analyze 100,000 plasma samples from their biobank after evaluating competitive proteomics platforms.

The collaboration represents one of the world's largest population health research studies, leveraging Singapore's multi-ethnic population. Standard BioTools' SomaScan platform was chosen for its superior proteome coverage, reproducibility, and service quality. The company has established itself as a leader in population proteomics, with SomaScan being used in over 30 biobank studies globally, including three major additions this year totaling nearly 160,000 samples.

Standard BioTools (NASDAQ:LAB) has scheduled its second quarter 2025 earnings conference call for August 11, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and operational progress.

Investors can join via phone using the following dial-in numbers: (888) 346-3970 for US domestic callers and (412) 902-4297 for international callers. The webcast will be accessible through the company's Investor Relations page and will be archived at investors.standardbio.com.

Illumina (NASDAQ: ILMN) has announced a definitive agreement to acquire SomaLogic from Standard BioTools for $350 million in cash, plus up to $75 million in performance-based milestones and royalties. The acquisition builds on their existing partnership since 2021 and aims to enhance Illumina's presence in the proteomics market while advancing their multiomics strategy. SomaLogic brings approximately 250 employees and facilities in Boulder, Colorado, including a CLIA- and CAP-certified lab. The deal combines SomaLogic's proteomics expertise with Illumina's NGS platforms, with the Illumina Protein Prep currently being used by 40 early-access customers globally. The transaction is expected to close in first half of 2026, subject to regulatory approvals, and become profitable by 2027 on a non-GAAP operating income basis.

Standard BioTools (NASDAQ: LAB) has announced the strategic sale of SomaLogic to Illumina (NASDAQ: ILMN) for up to $425 million. The deal includes $350 million in upfront cash payment and potential milestone payments of up to $75 million. Standard BioTools will retain rights to Single SOMAmer reagent commercialization and receive a 2% royalty on Illumina Protein Prep kit sales for 10 years. The transaction, expected to close in H1 2026, will significantly simplify Standard BioTools' operating structure and enable adjusted EBITDA break-even. Post-closing, the company expects to have at least $550 million in cash to fuel its inorganic growth strategy through M&A, targeting underappreciated assets in life sciences with strong margin potential and recurring revenue models.